High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center

Clinical Infectious Diseases

Volumn 63, Issue 7, 2016, Pages 954-958

  Aitken, Samuel L ^a,d   Tarrand, Jeffrey J ^b   Deshpande, Lalitagauri M ^e   Tverdek, Frank P ^a   Jones, Anne L ^a   Shelburne, Samuel A ^c   Prince, Randall A ^a,c,d   Bhatti, Micah M ^b   Rolston, Kenneth V I ^c   Jones, Ronald N ^e   Castanheira, Mariana ^e   Chemaly, Roy F ^c  

^a Division of Pharmacy   (United States)

^b Department of Laboratory Medicine ^*  (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF HOUSTON   (United States)

^e JMI LABORATORIES   (United States)

Author keywords

bacteremia; carbapenemase; ceftazidime avibactam; CRE; NDM

Indexed keywords

AMIKACIN; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; CEFEPIME; CILASTATIN PLUS IMIPENEM; COLISTIN; ERTAPENEM; MEROPENEM; METALLO BETA LACTAMASE; MINOCYCLINE; NEW DELHI METALLO BETA LACTAMASE 1; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE; BETA-LACTAMASE NDM-1; CEFTAZIDIME;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CHILD; CLINICAL ARTICLE; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION CONTROL; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEUS MIRABILIS; YOUNG ADULT; CANCER CENTER; DRUG EFFECTS; ENTEROBACTERIACEAE; ENZYMOLOGY; GENETICS; MICROBIOLOGY;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTEREMIA; BETA-LACTAMASES; CANCER CARE FACILITIES; CEFTAZIDIME; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84990966427     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw398     Document Type: Article

References (18)

1. Dortet L, Poirel L, Nordmann P. Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. Biomed Res Int 2014; 2014:249856.
2. Epstein L, Hunter JC, Arwady MA, et al. New Delhi metallo-beta-lactamaseproducing carbapenem-resistant Escherichia coli associated with exposure to duodenoscopes. JAMA 2014; 312:1447-55.
3. Li JJ, Munoz-Price LS, Spychala CN, DePascale D, Doi Y. New Delhi metallo-betalactamase-1-producing Klebsiella pneumoniae, Florida, USA. Emerg Infect Dis 2016; 22:744-6.
4. Guh AY, Bulens SN, Mu Y, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012-2013. JAMA 2015; 314:1479-87.
5. NDM-producing carbapenem-resistant Enterobacteriaceae (CRE) isolates reported to the Centers for Disease Control and Prevention (CDC) as of January 2015, by state. Available at: http://www.cdc.gov/hai/organisms/cre/TrackingCRE. html#CREmapNDM. Accessed 24 June 2016.
6. de Jager P, Chirwa T, Naidoo S, Perovic O, Thomas J. Nosocomial outbreak of New Delhi metallo-beta-lactamase-1-producing Gram-negative bacteria in South Africa: a case-control study. PLoS One 2015; 10:e0123337.
7. Bauer KA, Perez KK, Forrest GN, Goff DA. Review of rapid diagnostic tests used by antimicrobial stewardship programs. Clin Infect Dis 2014; 59(suppl 3):S134-45.
8. Walsh TR, Bolmstrom A, Qwarnstrom A, Gales A. Evaluation of a new Etest for detecting metallo-beta-lactamases in routine clinical testing. J Clin Microbiol 2002; 40:2755-9.
9. Zasowski EJ, Rybak JM, Rybak MJ. The beta-lactams strike back: Ceftazidime-Avibactam. Pharmacotherapy 2015; 35:755-70.
10. CLSI. M02-A12. Performance standards for antimicrobial disk susceptibility tests. 12th ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2015.
11. CLSI. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 10th ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2015.
12. Avycaz. Avycaz (ceftazidime-avibactam) package insert. Available at: http://www. accessdata.fda.gov/drugsatfda-docs/label/2015/206494s000lbl.pdf. Accessed 24 June 2016.
13. Castanheira M, Farrell SE, Deshpande LM, Mendes RE, Jones RN. Prevalence of beta-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 US hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010). Antimicrob Agents Chemother 2013; 57:3012-20.
14. Bharadwaj R, Joshi S, Dohe V, Gaikwad V, Kulkarni G, Shouche Y. Prevalence of New Delhi metallo-beta-lactamase (NDM-1)-positive bacteria in a tertiary care centre in Pune, India. Int J Antimicrob Agents 2012; 39:265-6.
15. Castanheira M, Mills JC, Costello SE, Jones RN, Sader HS. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from US hospitals (2011 to 2013) and characterization of beta-lactamase-producing strains. Antimicrob Agents Chemother 2015; 59:3509-17.
16. Humphries RM, Yang S, Hemarajata P, et al. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother 2015; 59:6605-7.
17. Ho PL, Li Z, Lai EL, Chiu SS, Cheng VC. Emergence of NDM-1-producing Enterobacteriaceae in China. J Antimicrob Chemother 2012; 67:1553-5.
18. Crandon JL, Nicolau DP. Human simulated studies of aztreonam and aztreonamavibactam to evaluate activity against challenging gram-negative organisms, including metallo-beta-lactamase producers. Antimicrob Agents Chemother 2013; 57:3299-306.